TWI BIOTECHNOLOGY, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.65 TWD | +1.11% |
|
+5.00% | -2.50% |
| 04-09 | TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 1.23B 38M 51.96M |
|---|---|---|---|---|---|
| Net income 2022 | -76M -2.35M -3.21M | Net income 2023 | -171M -5.29M -7.23M | EV / Sales 2022 | - |
| Net cash position 2022 | 158M 4.88M 6.67M | Net cash position 2023 | 316M 9.76M 13.35M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-13.1
x | P/E ratio 2023 |
-6
x | Employees | 21 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.35% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.11% | ||
| 1 week | +5.00% | ||
| Current month | +8.33% | ||
| 1 month | +6.23% | ||
| 3 months | +4.20% | ||
| 6 months | -7.46% | ||
| Current year | -2.50% |
1 week
12.95
14.35
1 month
11.8014.35
Current year
11.1514.95
1 year
11.1521.30
3 years
10.0026.00
5 years
5.1932.70
10 years
5.1994.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chu Chun Weng
CEO | Chief Executive Officer | - | - |
Lien I Ho
DFI | Director of Finance/CFO | - | - |
Kuang Wei Lu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Yan Chang
BRD | Director/Board Member | - | 21-08-15 |
Jonas Wang
BRD | Director/Board Member | - | 19-06-04 |
Yi Chun Wu
CHM | Chairman | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-21 | 13.65 | +1.11% | 68,215 |
| 24-06-20 | 13.5 | -2.53% | 251,713 |
| 24-06-19 | 13.85 | +4.14% | 862,063 |
| 24-06-18 | 13.3 | +1.92% | 284,555 |
| 24-06-17 | 13.05 | +0.38% | 102,301 |
End-of-day quote Taipei Exchange, June 20, 2024
More quotes
TWi Biotechnology, Inc. is a Taiwan-based clinical stage biopharmaceutical company specializing in the development of new drugs for unmet medical needs, especially in diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. Its product development pipeline includes two drug candidates for treating type II diabetes, arthritis, and immunodermatology diseases and others. Itâs still in the research and development stage, its operating income is the contract revenue from the signing of the contract with the Castal Creek Pharmaceuticals (CCP) about its drug AC-203 for the treatment of epidermolysis bullosa (EB). It mainly aims at America market.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.50% | 36.93M | |
| +34.14% | 51.12B | |
| -6.54% | 39.4B | |
| +34.92% | 38.48B | |
| +12.62% | 26.36B | |
| -12.11% | 26.22B | |
| -13.43% | 20.96B | |
| +43.73% | 14.02B | |
| +31.81% | 12.49B | |
| -4.54% | 11.61B |
- Stock Market
- Equities
- 6610 Stock
